Phaseline

Targets › SPTLC1

SPTLC1 (Serine palmitoyltransferase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Jun 2031.

Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases. The SPT complex is also composed of SPTLC2 or SPTLC3 and SPTSSA or SPTSSB. Within this complex, the heterodimer with SPTLC2 or SPTLC3 forms the catalytic core. (UniProt, O15269)

Open in Phaseline: the race on SPTLC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Leal TherapeuticsLTX-002
Antisense oligonucleotide (ASO) targeting SPTLC1 mRNA
SPTLC1Phase 1Amyotrophic Lateral SclerosisJun 2031

Conditions

Amyotrophic Lateral Sclerosis (1)

Modalities

small molecule (1)

Companies

Leal Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.